Photodynamic therapy targeted to tumor-induced angiogenic vessels

Kurohane, Kohta; Tominaga, Akihide; Sato, Katsuhiko; North, John R.; Namba, Yukihiro; Oku, Naoto

doi:10.1016/s0304-3835(01)00475-x

Cited by 90 publications

(83 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, 15-min PDT effectively damaged angiogenic vasculature in dorsal air sac angiogenic model mouse. 82) Additionally, cationic molecules are considered useful for enhancing interaction of the photosensitizer entrapped in liposomes with the vascular endothelial cells of angiogenic vessels. It would be expected that cationic molecules would adhere to the anionic plasma membrane by electrostatic interaction.…”

Section: Anti-neovascular Therapy (Anet)mentioning

confidence: 99%

Cancer Anti-angiogenic Therapy

Shimizu

Oku

2004

Biological & Pharmaceutical Bulletin

Self Cite

View full text Add to dashboard Cite

Tumor angiogenesis affords new targets for cancer therapy, since inhibition of angiogenesis suppresses tumor growth by cutting out the supply of oxygen and nutrients. Anti-angiogenic therapy is thought to be free of the severe side effects that are usually seen with cytotoxic anticancer drugs. Furthermore, anti-angiogenic therapy is thought not only to eradicate primary tumor tissues, but also to suppress tumor metastases. However, it is uncertain whether this therapy causes tumor regression because it inhibits only angiogenic events. Recently, a novel anti-angiogenic therapy called anti-neovascular therapy (ANET) has become notable. This therapy inflicts indirect lethal damage on tumor cells by damaging newly formed blood vessels using anti-cancer drugs targeting the angiogenic vasculature, since cytotoxic anti-cancer drugs cause damage to proliferating neovascular endothelial cells as well as tumor cells. Moreover, neovascular endothelial cells would not be expected to acquire drug-resistance. Traditional chemotherapy, which directly targets tumor cells, has potential problems such as low specificity and severe side effects. On the contrary, in ANET, severe side effects may be suppressed, since traditional anti-cancer agents are delivered to the neovessels by DDS technology. Besides the usage of DDS technology, antineovascular scheduling of chemotherapy, or metronomic-dosing chemotherapy, has also been attempted in which anti-cancer drugs are administered on a schedule to damage neovessels. In this review, we describe traditional anti-angiogenic therapy and ANET. We also discuss anti-angiogenic cancer photodynamic therapy (PDT), since PDT is clinically applied to treat age-related macular degeneration (AMD), in which uncontrolled angiogenesis occurs.

show abstract

Section: Anti-neovascular Therapy (Anet)mentioning

confidence: 99%

Cancer Anti-angiogenic Therapy

Shimizu

Oku

2004

Biological & Pharmaceutical Bulletin

Self Cite

View full text Add to dashboard Cite

show abstract

“…Consequently, Kurobane et al showed that a liposomal formulation of benzoporphyrin derivative monoacid PDT can be used to target the angiogenic vasculature [107]. Using a murine dorsal air sac model and a Meth A sarcoma mouse model they found evidence that direct targeting of the neovasculature is possible and can result in strong tumor suppression.…”

Section: Anti-angiogenesismentioning

confidence: 99%

Platelets, photosensitizers, and PDT

Senge

Radomski

2013

Photodiagnosis and Photodynamic Therapy

View full text Add to dashboard Cite

SummaryPhotodynamic therapy (PDT) has both direct cell and indirect vascular effects. Both are well established and the latter has given rise to specifically target angiogenesis in PDT treatments. While the vascular effects are well understood, further advances in antiangiogenesis require a detailed understanding of PDT effects at the microvasculature level. Although some of the earliest investigations of PDT noted effects on platelet aggregation the importance of their interaction with endothelial cells and the crucial role of various signaling pathways is only now emerging. This review aims to give a general overview of PDT related studies on platelets, vascular effects, and their interaction with endothelial cells to indicate the potential for studies in this area.Abbreviations: ALA --aminolevulinic acid; AMD -age-related macular degeneration; ANET -anti-neovascular therapy; BGF -basic fibroblast growth factor; DHEdihaematoporphyrin ether; EDRF -endothelium-derived relaxing factor; epithelial growth factor -EGF; HIF-1 -hypoxia-inducible factor 1; HpD -haematoporphyrin derivative; IL -interleukin; PAF -platelet activating factor; PDT -photodynamic therapy; PS -photosensitizer; transforming growth factor 1 -TGF-1; TNF -tumor necrosis factor.

show abstract

“…We thus sought to deliver BPD-MA to cancer angiogenic endothelial cells and damaged these cells by laser irradiation. For this purpose, laser irradiation was performed early after the injection of liposomal BPD-MA 37) or liposomes modified with polycations [38][39][40] or APRPG peptides. 41,42) Interestingly, BPD-MA in PEGylated liposomes and that in APRPG-PEG-modified liposomes similarly accumulated in tumors of tumor-bearing mice 3 h after injection (Fig.…”

Section: Introductionmentioning

confidence: 99%

Innovations in Liposomal DDS Technology and Its Application for the Treatment of Various Diseases

Oku

2017

Biological & Pharmaceutical Bulletin

Self Cite

View full text Add to dashboard Cite

Liposomes have been widely used as drug carriers in the field of drug delivery systems (DDS), and they are thought to be ideal nano-capsules for targeting DDS after being injected into the bloodstream. In general, DDS drugs meet the needs of aged and super-aged societies, since the administration route of drugs can be changed, the medication frequency reduced, the adverse effects of drugs suppressed, and so on. In fact, a number of liposomal drugs have been launched and used worldwide including liposomal anticancer drugs, and these drugs have appeared on the market owing to various innovations in liposomal DDS technologies. The accumulation of long-circulating liposomes in cancer tissue is driven by the enhanced permeability and retention (EPR) effect. In this review, liposome-based targeting DDS for cancer therapy is briefly discussed. Since cancer angiogenic vessels are the ideal target of drug carriers after their injection and are critical for cancer growth, damaging of these neovessels has been an approach for eradicating cancer cells. Also, the usage of liposomal DDS for the treatment of ischemic stroke is possible, since we observed that PEGylated liposomes accumulate in the site of cerebral ischemia in transient middle cerebral artery occlusion (t-MCAO) model rats. Interestingly, liposomes carrying neuroprotectants partly suppress ischemia/reperfusion injury of these model rats, suggesting that the EPR effect also works in ischemic diseases by causing an increase in the permeability of the blood vessel endothelium. The potential of liposomal DDS against life-threatening diseases might thus be attractive for supporting long-lived societies.

show abstract

Photodynamic therapy targeted to tumor-induced angiogenic vessels

Cited by 90 publications

References 13 publications

Cancer Anti-angiogenic Therapy

Cancer Anti-angiogenic Therapy

Platelets, photosensitizers, and PDT

Innovations in Liposomal DDS Technology and Its Application for the Treatment of Various Diseases

Contact Info

Product

Resources

About